Drug Trial Radar · NCT06590740
Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.
Last checked: Nov 20, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,000
Actual
Start
Oct 18, 2024
Primary completion
Sep 3, 2025
Study completion Sep 3, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, prospective, single-arm, interventional clinical study to predict the response to budesonide-formoterol treatment in patients with chronic dry or nocturnal cough by determining a cut off value of FeNO. In this study, the response to ICS/LABA treatment is defined as reduction in cough VAS score from baseline of ≥30 mm after 8 weeks of ICS/LABA treatment. Subjects will be treated with Symbicort® 160/4.5 mcg, 1 puff, BID for 8 weeks with 4 study visits: Visit 1 (Day 0), Visit 2 (week 4) and Visit 3, end of study (week 8) and Visit 4, 4 weeks after treatment discontinuation, (week 12). Baseline data will be collected at Day-5 to Day0. This study will be conducted at around 40 study sites in China. Approximately 1000 patients (age ≥18 years old) with dry cough or nocturnal cough symptoms for at least 8 weeks and no other obvious cause for their cough will be enrolled into this study.
Conditions
- Cough-Variant Asthma
Interventions
Budesonide-Formoterol treatmentDrug
Budesonide 160 μg/formoterol 4.5 μg, 1 inhalation, BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- To obtain a cut-off value for FeNO which can be used to distinguish responsiveness to 8 weeks treatment of Budesonideformoterol (based on visual analog scale [VAS]).Time frame: 8 weeks
Locations
39 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Benxi, China
Research Site
Chengdu, China
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Dongguan, China
Research Site
Fenyang, China
Research Site
Fuzhou, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Guiyang, China
Research Site
Heifei, China
Research Site
Heze, China
Research Site
Huizhou, China
Research Site
Jiaxing, China
Research Site
Jinhua, China
Research Site
Liuzhou, China
Research Site
Nanchang, China
Research Site
Nanjing, China
Research Site
Nanyang, China
Research Site
Quanzhou, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shangqiu, China
Research Site
Shenzhen, China
Research Site
Shijiazhuang, China
Research Site
Suzhou, China
Research Site
Taiyuan, China
Research Site
Taiyuan, China
Research Site
Weifang, China
Research Site
Wenzhou, China
Research Site
Wenzhou, China
Research Site
Xi'an, China
Research Site
Xiangtan, China
Research Site
Yantai, China
Research Site
Zhengzhou, China
Research Site
Zunyi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.